FDA Clears Toshiba's Infinix 4D CT with Aquilion Prime CT Configuration

March 13, 2015—Combining interventional lab and CT technology, Toshiba America Medical Systems, Inc. announced that the US Food and Drug Administration (FDA) has cleared the Infinix 4D CT with the company’s Aquilion Prime CT system configuration. The Infinix 4D CT previously received FDA clearance with the Infinix Elite cardiovascular x-ray system and Aquilion One Vision edition CT system configuration.

According to Toshiba, the Infinix 4D CT is an all-in-one interventional lab and CT solution to deliver real-time CT images during procedures instead of CT-like images. The system’s SureGuidance technology allows for automatic transition between modalities to improve workflow. In addition, it saves time by allowing clinicians to perform CT and interventional procedures within the same room and verify treatment success after procedures.

Clinically, the Infinix 4D CT maximizes workflow of oncology and cardiac procedures by providing interventionists with CT images for the target anatomy. Clinicians can adjust the procedure with real-time CT studies instead of relying on CT images taken at an earlier time, stated the company.

Toshiba advised that it will showcase the new product at its booth (#1916) at ACC.15, the American College of Cardiology annual scientific session on March 14–16 in San Diego, California.

Also at ACC.15, Toshiba is introducing cardiac diagnostic technology: the Aquilion One Vision edition CT system with the PureVision CT detector and the Aplio Platinum Series CV ultrasound systems.

Toshiba stated that the Aquilion One Vision edition CT system with the PureVision CT detector for diagnosing patients produces high-quality images and a fast workflow by capturing the entire heart in one rotation with 640 slices. Additionally, the system can accommodate more patients with its ability to image bariatric patients and those with high heart rates with a gantry rotation of 0.275 seconds and a large bore (78 cm). The system’s lesion visualization and myocardial perfusion capabilities allow clinicians to visualize and quantify myocardial ischemia with a single CT examination. Toshiba’s third-generation adaptive iterative dose reconstruction software, AIDR 3D, offers simplified dose reduction by producing the image quality needed for diagnosis at low dose.

The Aplio 500 Platinum CV and Aplio 300 Platinum CV feature two-dimensional wall motion tracking, spectral and color Doppler, and Toshiba’s latest suite of guidance and workflow technologies. The systems provide detail and resolution throughout the entire field of view, providing excellent definition of the endocardium, which results in an accurate and easy-to-use two-dimensional strain resolution. Toshiba’s wall motion tracking technology allows doctors to quantify isolated movement within the heart to assist with detection of cardiotoxicity, noted Toshiba.